NEW YORK (GenomeWeb News) – Investment firm ISI Group on Wednesday downgraded shares of Hologic, saying the company's new management will need time to turn the business around.

ISI downgraded Hologic's shares to Buy from a previous Strong Buy rating, but maintained earlier EPS estimates of $1.35 for Fiscal Year 2014; $1.55 for FY 2015; and $1.75 for FY 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.